2,2′-{[2-(Pyridin-2-yl)-1,3-diazinane-1,3-diyl]bis(methylene)}diphenol

por Bortoluzzi, Adailton J., Terra, Geovana G.
Publicado 2012

A population pharmacokinetic and pharmacokinetic‐pharmacodynamic analysis of vupanorsen from phase I and phase II studies

por Ahn, Jae Eun, Terra, Steven G., Liu, Jing
Publicado 2023

Di-μ-chlorido-bis­{[2-({[2-(2-pyrid­yl)eth­yl](2-pyridylmeth­yl)amino}meth­yl)phenol]zinc(II)} bis­(perchlorate) dihydrate

por Coelho, Sara E., Terra, Geovana G., Bortoluzzi, Adailton J.
Publicado 2010

2-Phenyl-5-(trifluoro­meth­yl)pyrazol-3(2H)-one

por Gallardo, Hugo, Girotto, Edivandro, Bortoluzzi, Adailton J., Terra, Geovana G.
Publicado 2009

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials

por Liu, Jie, Pong, Annpey, Gallo, Silvina, Darekar, Amanda, Terra, Steven G.
Publicado 2019

Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

por Aronson, Ronnie, Frias, Juan, Goldman, Allison, Darekar, Amanda, Lauring, Brett, Terra, Steven G.
Publicado 2018

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials

por Gallo, Silvina, Calle, Roberto A., Terra, Steven G., Pong, Annpey, Tarasenko, Lisa, Raji, Annaswamy
Publicado 2020

Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus

por Heymsfield, Steven B., Raji, Annaswamy, Gallo, Silvina, Liu, Jie, Pong, Annpey, Hannachi, Hakima, Terra, Steven G.
Publicado 2020

Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial

por Gallo, Silvina, Charbonnel, Bernard, Goldman, Allison, Shi, Harry, Huyck, Susan, Darekar, Amanda, Lauring, Brett, Terra, Steven G.
Publicado 2019

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus

por Sahasrabudhe, V., Terra, S. G., Hickman, A., Saur, D., Shi, H., O'Gorman, M., Zhou, Z., Cutler, D. L.
Publicado 2017

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials

por Patel, Shrita, Hickman, Anne, Frederich, Robert, Johnson, Susan, Huyck, Susan, Mancuso, James P., Gantz, Ira, Terra, Steven G.
Publicado 2020

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects

por Dawra, Vikas Kumar, Liang, Yali, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Cutler, David, Sahasrabudhe, Vaishali
Publicado 2019

A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults

por Fukuhara, Kei, Furihata, Kenichi, Matsuoka, Nobushige, Itamura, Rio, Ramos, Vesper, Hagi, Toshiaki, Kalluru, Hindu, Bramson, Candace, Terra, Steven G., Liu, Jing
Publicado 2023

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

por Miller, Sam, Krumins, Tania, Zhou, Haojin, Huyck, Susan, Johnson, Jeremy, Golm, Gregory, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado 2018

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus

por Liu, Jie, Patel, Shrita, Cater, Nilo B., Wu, Larry, Huyck, Susan, Terra, Steven G., Hickman, Anne, Darekar, Amanda, Pong, Annpey, Gantz, Ira
Publicado 2020

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

por Grunberger, George, Camp, Sarah, Johnson, Jeremy, Huyck, Susan, Terra, Steven G., Mancuso, James P., Jiang, Zhi Wei, Golm, Gregory, Engel, Samuel S., Lauring, Brett
Publicado 2017

Bioequivalence of Ertugliflozin/Metformin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components

por Dawra, Vikas Kumar, Liang, Yali, Wei, Hua, Pelletier, Kathleen, Shi, Haihong, Hickman, Anne, Bass, Almasa, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Sahasrabudhe, Vaishali
Publicado 2019

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

por Fediuk, Daryl J., Nucci, Gianluca, Dawra, Vikas Kumar, Cutler, David L., Amin, Neeta B., Terra, Steven G., Boyd, Rebecca A., Krishna, Rajesh, Sahasrabudhe, Vaishali
Publicado 2020

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

por Hollander, Priscilla, Liu, Jie, Hill, Julie, Johnson, Jeremy, Jiang, Zhi Wei, Golm, Gregory, Huyck, Susan, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado 2017

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects

por Dawra, Vikas Kumar, Cutler, David L., Zhou, Susan, Krishna, Rajesh, Shi, Haihong, Liang, Yali, Alvey, Christine, Hickman, Anne, Saur, Didier, Terra, Steven G., Sahasrabudhe, Vaishali
Publicado 2018